UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy -- patients' views of early cessation of therapy.

D'Souza, R; Main, J; Crossey, M; Rosenberg, W; Murray-Lyon, IM; Hayward, C; Foster, GR; (2005) Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy -- patients' views of early cessation of therapy. Aliment Pharmacol Ther , 21 (1) 43 - 47. 10.1111/j.1365-2036.2004.02295.x.

Full text not available from this repository.

Abstract

Current therapy for chronic hepatitis C infection involves a course of pegylated interferon and ribavirin. Patients who do not show a virological response after 12 weeks of therapy have a low probability of sustained virological response and it is therefore recommended that such patients stop treatment.

Type:Article
Title:Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy -- patients' views of early cessation of therapy.
Location:England
DOI:10.1111/j.1365-2036.2004.02295.x
Language:English
Keywords:Adult, Aged, Antiviral Agents, Attitude to Health, Cohort Studies, Drug Resistance, Viral, Drug Therapy, Combination, Female, Hepatitis C, Chronic, Humans, Interferon-alpha, Male, Middle Aged, Polyethylene Glycols, Recombinant Proteins, Ribavirin, Treatment Failure

Archive Staff Only: edit this record